TY - JOUR
T1 - Shared and divergent phase separation and aggregation properties of brain-expressed ubiquilins
AU - Gerson, Julia E.
AU - Linton, Hunter
AU - Xing, Jiazheng
AU - Sutter, Alexandra B.
AU - Kakos, Fayth S.
AU - Ryou, Jaimie
AU - Liggans, Nyjerus
AU - Sharkey, Lisa M.
AU - Safren, Nathaniel
AU - Paulson, Henry L.
AU - Ivanova, Magdalena I.
N1 - Funding Information:
This work was supported by NIH 9R01NS096785-06 (HLP, MII), 1P30AG053760-01 (HLP), F32-AG059362-01 (JEG), T32-NS007222-36 (JEG), the Michigan Alzheimer’s Disease Association (JEG), the Amyotrophic Lateral Sclerosis Foundation (HLP), the American Parkinson’s Disease Association (MII), UM Protein Folding Disease Initiative (LMS, HLP, MII) and M-cubed (MII). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - The brain-expressed ubiquilins, UBQLNs 1, 2 and 4, are highly homologous proteins that participate in multiple aspects of protein homeostasis and are implicated in neurodegenerative diseases. Studies have established that UBQLN2 forms liquid-like condensates and accumulates in pathogenic aggregates, much like other proteins linked to neurodegenerative diseases. However, the relative condensate and aggregate formation of the three brain-expressed ubiquilins is unknown. Here we report that the three ubiquilins differ in aggregation propensity, revealed by in-vitro experiments, cellular models, and analysis of human brain tissue. UBQLN4 displays heightened aggregation propensity over the other ubiquilins and, like amyloids, UBQLN4 forms ThioflavinT-positive fibrils in vitro. Measuring fluorescence recovery after photobleaching (FRAP) of puncta in cells, we report that all three ubiquilins undergo liquid–liquid phase transition. UBQLN2 and 4 exhibit slower recovery than UBQLN1, suggesting the condensates formed by these brain-expressed ubiquilins have different compositions and undergo distinct internal rearrangements. We conclude that while all brain-expressed ubiquilins exhibit self-association behavior manifesting as condensates, they follow distinct courses of phase-separation and aggregation. We suggest that this variability among ubiquilins along the continuum from liquid-like to solid informs both the normal ubiquitin-linked functions of ubiquilins and their accumulation and potential contribution to toxicity in neurodegenerative diseases.
AB - The brain-expressed ubiquilins, UBQLNs 1, 2 and 4, are highly homologous proteins that participate in multiple aspects of protein homeostasis and are implicated in neurodegenerative diseases. Studies have established that UBQLN2 forms liquid-like condensates and accumulates in pathogenic aggregates, much like other proteins linked to neurodegenerative diseases. However, the relative condensate and aggregate formation of the three brain-expressed ubiquilins is unknown. Here we report that the three ubiquilins differ in aggregation propensity, revealed by in-vitro experiments, cellular models, and analysis of human brain tissue. UBQLN4 displays heightened aggregation propensity over the other ubiquilins and, like amyloids, UBQLN4 forms ThioflavinT-positive fibrils in vitro. Measuring fluorescence recovery after photobleaching (FRAP) of puncta in cells, we report that all three ubiquilins undergo liquid–liquid phase transition. UBQLN2 and 4 exhibit slower recovery than UBQLN1, suggesting the condensates formed by these brain-expressed ubiquilins have different compositions and undergo distinct internal rearrangements. We conclude that while all brain-expressed ubiquilins exhibit self-association behavior manifesting as condensates, they follow distinct courses of phase-separation and aggregation. We suggest that this variability among ubiquilins along the continuum from liquid-like to solid informs both the normal ubiquitin-linked functions of ubiquilins and their accumulation and potential contribution to toxicity in neurodegenerative diseases.
UR - http://www.scopus.com/inward/record.url?scp=85099191600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099191600&partnerID=8YFLogxK
U2 - 10.1038/s41598-020-78775-4
DO - 10.1038/s41598-020-78775-4
M3 - Article
C2 - 33431932
AN - SCOPUS:85099191600
SN - 2045-2322
VL - 11
JO - Scientific Reports
JF - Scientific Reports
IS - 1
M1 - 287
ER -